Literature DB >> 1334693

Expression of the HPV16 E7 gene generates proliferation in stratified squamous cell cultures which is independent of endogenous p53 levels.

R A Blanton1, M D Coltrera, A M Gown, C L Halbert, J K McDougall.   

Abstract

Monolayer cultures of human foreskin and ectocervical epithelial cells were infected with retroviral vectors expressing HPV16 oncogenes, selected for G418 resistance, and cultured organotypically so that they reformed the fully differentiated, stratified squamous tissues from which they were originally derived. Expression of HPV16 E7 prevented cell cycle withdrawal in the suprabasal layers of these stratified cultures but had no effect on terminal differentiation. Cultures expressing E7 alone and those coexpressing E6 and E7 were identical in terms of suprabasal proliferation and terminal differentiation, but they differed in expression of the endogenous tumor suppressor protein p53. Immunohistochemically detectable p53 protein localized to the proliferative compartment in normal and E7-containing cultures but was undetectable in those cultures which coexpressed E6 and E7. This result suggests that E7-induced suprabasal proliferation is independent of the steady-state level of p53.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1334693

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  11 in total

1.  Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes.

Authors:  A M Helt; D A Galloway
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Initiation of DNA synthesis by human papillomavirus E7 oncoproteins is resistant to p21-mediated inhibition of cyclin E-cdk2 activity.

Authors:  M N Ruesch; L A Laimins
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

3.  Restoration of telomeres in human papillomavirus-immortalized human anogenital epithelial cells.

Authors:  A J Klingelhutz; S A Barber; P P Smith; K Dyer; J K McDougall
Journal:  Mol Cell Biol       Date:  1994-02       Impact factor: 4.272

4.  Disruption of the G1/S transition in human papillomavirus type 16 E7-expressing human cells is associated with altered regulation of cyclin E.

Authors:  L G Martin; G W Demers; D A Galloway
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

5.  The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2.

Authors:  D L Jones; R M Alani; K Münger
Journal:  Genes Dev       Date:  1997-08-15       Impact factor: 11.361

6.  Inactivation of both the retinoblastoma tumor suppressor and p21 by the human papillomavirus type 16 E7 oncoprotein is necessary to inhibit cell cycle arrest in human epithelial cells.

Authors:  Anna-Marija Helt; Jens Oliver Funk; Denise A Galloway
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  Human papillomaviruses: a growing field.

Authors:  Denise A Galloway
Journal:  Genes Dev       Date:  2009-01-15       Impact factor: 11.361

8.  p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein.

Authors:  R J Slebos; M H Lee; B S Plunkett; T D Kessis; B O Williams; T Jacks; L Hedrick; M B Kastan; K R Cho
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

9.  Clinical Significance of p53 and p16(ink4a) Status in a Contemporary North American Penile Carcinoma Cohort.

Authors:  Kamran Zargar-Shoshtari; Philippe E Spiess; Anders E Berglund; Pranav Sharma; Julio M Powsang; Anna Giuliano; Anthony M Magliocco; Jasreman Dhillon
Journal:  Clin Genitourin Cancer       Date:  2015-12-23       Impact factor: 2.872

10.  Abrogation of growth arrest signals by human papillomavirus type 16 E7 is mediated by sequences required for transformation.

Authors:  G W Demers; E Espling; J B Harry; B G Etscheid; D A Galloway
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.